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SOX2 overlapping transcript (SOX2OT) is a long non-coding RNA which harbors one
of the major regulators of pluripotency, SOX2 gene, in its intronic region. SOX2OT
gene is mapped to human chromosome 3q26.3 (Chr3q26.3) locus and is extended
in a high conserved region of over 700 kb. Little is known about the exact role of
SOX2OT; however, recent studies have demonstrated a positive role for it in transcription
regulation ofSOX2 gene. Similar to SOX2, SOX2OT is highly expressed in embryonic stem
cells and down-regulated upon the induction of differentiation. SOX2OT is dynamically
regulated during the embryogenesis of vertebrates, and delimited to the brain in adult
mice and human. Recently, the disregulation of SOX2OT expression and its concomitant
expression with SOX2 have become highlighted in some somatic cancers including
esophageal squamous cell carcinoma, lung squamous cell carcinoma, and breast
cancer. Interestingly, SOX2OT is differentially spliced into multiple mRNA-like transcripts
in stem and cancer cells. In this review, we are describing the structural and functional
features of SOX2OT, with an emphasis on its expression signature, its splicing patterns
and its critical function in the regulation of SOX2 expression during development and
tumorigenesis.
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Introduction
According to the recent genome-wide studies, most of the human genome is transcribed, yielding
a complex network of large and small RNA molecules in human cells. However, only 1–2% of the
transcripts have the capacity for protein translation (Kapranov et al., 2007; Guttman et al., 2009).
The new class of long (or large) non-coding RNAs (lncRNAs) comprises the most proportion of
the human transcriptome. Little is known about the exact functional roles of lncRNAs in human.
Nevertheless, some recent studies have reported dysregulations of lncRNAs in several human
disorders. LncRNAs key roles in the regulation of pluripotency, stem cells differentiation, and
tumorigenesis are emerging (Perez et al., 2007; Gupta et al., 2010; Loewer et al., 2010; Esteller, 2011;
Ng et al., 2011; Prensner and Chinnaiyan, 2011). Furthermore, a number of studies have achieved
toward a therapeutic effect for some genetic disorders by targeting an lncRNA in vitro and in vivo
(Gupta et al., 2010; Gutschner et al., 2013; Meng et al., 2015).
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SOX2 is a HMG-box transcription factor which is essential
for the maintenance of self-renewal and the pluripotency of
undifferentiated embryonic stem cells (Avilion et al., 2003; Fong
et al., 2008). More interestingly, SOX2 along with OCT4, c-
Myc and Klf4 plays a critical role in the generation of induced
pluripotent stem cells (iPSC) from both adult human and mouse
somatic cells (Takahashi and Yamanaka, 2006; Takahashi et al.,
2007). Recently, it has been suggested that SOX2 promotes tumor
initiation and controls cancer stem cell properties in squamous
cell carcinoma (SCC) of the skin tumors (Boumahdi et al.,
2014). The single-exon SOX2 gene was mapped to the human
chromosome 3q26.3 (Chr3q26.3) locus, where it is embedded
within the intronic region of a multi-exon lncRNA, known as
SOX2 overlapping transcript (SOX2OT) which transcribed in the
same orientation as SOX2 (Fantes et al., 2003). While little is
known about the exact role of SOX2OT, recent studies have
demonstrated a positive role for it in the regulation of SOX2 gene
in human stem cells (Amaral et al., 2009; Shahryari et al., 2014).
Human SOX2OT gene has a high nucleotide identity with its
ortholog in mouse and other vertebrates, demonstrating its high
degree of evolutionarily conservation. The multi-exon SOX2OT
has no open reading frame (ORF), but is spliced into several
mRNA-like transcripts with the longest one of approximately
3.5 kb in human (Amaral et al., 2009; Shahryari et al., 2014).
Close concomitant expression patterns of SOX2OT and SOX2
in stem cells and some human cancers, have all suggested that
they may be co-regulated and involved in similar molecular
pathways. Accordingly, some recent reports have demonstrated
the transcriptional regulation of SOX2 by SOX2OT (Amaral et al.,
2009; Askarian-Amiri et al., 2014; Hou et al., 2014; Shahryari
et al., 2014).
In this review, we have delineated the complex structure and
functional features of SOX2OT locus, with more emphasis on
its expression and splicing patterns, and its potential role in the
regulation of SOX2 expression during the development and cancer
progression.
Genomic Architecture of SOX2OT Gene
Region in Vertebrates
SOX2OT gene with the official symbol of SOX2-OT (also
known as NCRNA00043) was originally mapped to the
human chromosome 3q26.3-q27 locus [current location of
NC_000003.12 (181056680..181742228)], and harbors one of
the main regulators of pluripotency, SOX2 gene [also known as
ANOP3 and MCOPS3, with current location of NC_000003.12
(181711924..181714436)], in its intronic region overlapping in the
same transcriptional orientation (Fantes et al., 2003). SOX2OT
gene is located and extended in a highly conserved region of
over 700 kb in human and other vertebrates (Fantes et al., 2003;
Amaral et al., 2009; Figure 1A).
Amplification of several genomic regions at 3q26-qter
chromosome is associated with multiple human cancers (Massion
et al., 2002; Jiang et al., 2004). The gene amplification events in
those regions, particularly in q26–q29 region of chromosome
3, are present in the multiple types of SCCs of different tissues
including lung, head and neck, esophagus, and cervix (Gebhart
and Liehr, 2000; Balsara and Testa, 2002; Bass et al., 2009).
Interestingly, a 2 Mb gained/amplified genomic region in 3q26.3
which encompasses SOX2 and SOX2OT has been reported in
lung SCC (Hussenet et al., 2010).
Chromatin modification maps of chromosome 3q26.3-q27
acquired by chromatin immune precipitation sequencing (ChIP-
Seq) data represented several transcription start sites (TSSs) for
SOX2OT gene (Mikkelsen et al., 2007; Amaral et al., 2009).
Those promoter regions embedded within 1–7 non-coding highly
conserved sequence blocks in vertebrates known as highly
conserved elements (HCEs), probably are associated with the
regulatory region of SOX2OT. These blocks of transposon-free
regions with over 5 kb long have remained resistant to transposon
invasion throughout vertebrate evolution and encompassed
regulatory sequences controlling the expression of genes that are
involved in early development (Simons et al., 2006; Amaral et al.,
2009).
Interestingly, analysis of the alternative TSSs of Sox2ot
orthologous in various vertebrates demonstrated the existence
of a distal promoter, located over 500 kb upstream of the
SOX2OT sequence in mouse and human (SOX2OT refers
to human and Sox2ot to non-human). This distal promoter
region which is associated with the transposon-free region,
highly positional conserved elements, and histone modification
marks of promoters, created a novel isoform of Sox2ot termed
Sox2dot (Sox2 distal overlapping transcript) which has HCE
1 with an enhancer-like function in the mouse’s developing
forebrain (Amaral et al., 2009). Here, we bioinformatically
analyzed the potential binding sites for transcription factors
in a highly conserved genomic regions upstream of SOX2OT
and SOX2DOT. As illustrated in Figure 1, the data represent
the existence of binding sites of several transcription factors
involved in cancer progression as well as stem cells pluripotency
and differentiation in those regulatory regions. Noticeably, the
number and distribution of binding sites of some transaction
factors belonging to POU domain and HMG-box families is
surprising (Figures 1B,C).
Primary sequence analysis of sox2ot in vertebrates including
fish, reptiles, amphibians and mammals highlighted some highly
conserved regions, including a 400-nt segment in exons near to
SOX2 gene, as well as an upstream region with more than 90%
identity between mouse and human genomes. However, there is
only a low degree of conservation when full length sequence of
SOX2OT gene (750 kb) is compared among different species
(Amaral et al., 2009; Figure 2).
Splicing Patterns of SOX2OT Gene in
Human and Other Vertebrates
Protein-coding capacity parameters including ORF length,
synonymous versus non-synonymous base substitution rates,
and similarity to known proteins demonstrated that human and
mouse SOX2OT/Sox2ot full-length sequences have no significant
protein-coding potential. Nevertheless, there is a possibility for
generation of some small peptides, encoded by some transcripts
(Dinger et al., 2008; Amaral et al., 2009). Mark signs of mRNAs
including a lot of cap and poly Adenine signals suggest that
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FIGURE 1 | Genomic architecture of Chr3q26.33 region in human and
vertebrates. (A) The banding pattern of chromosome 3 and location of
SOX2OT locus of 3q26.33 is presented according to the UCSC genome
browser (h19 assembly). (B) The conserved transcription factor binding sites is
presented at upstream of human genomic regions of SOX2OT and the isoform
of SOX2DOT. The binding sites distribution for multiple transcription factors of
POU domain and HMG-box families is noticeable. (C) A high degree of
conservation at upstream of genomic regions of SOX2OT and SOX2DOT in 100
vertebrates is presented, using Multiz alignment program (adopted from
http://genome.ucsc.edu).
FIGURE 2 | A schematic representation of comparative
genomics locus of SOX2OT in different species. The evolutionary
conserved regions (ECR) of chr3:181236624-18150288 adapted from
ECR browser (http://ecrbrowser.dcode.org) on human (hg19) is
presented. The data is compared with some well-known vertebrates
including rhesus, dog, mouse, chicken, Xenopus, and fish. The ECR
length and similarity considered as browser default. The UCSC known
genes of SOX2OT and SOX2 locating in the region is shown at the
bottom. Notice that the most conserved regions are concentrated
around SOX2 overlapping region.
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FIGURE 3 | Schematic representative of human SOX2OT gene and its
splicing patterns. (A) Multi-exon gene of SOX2OT is located on human
Chr3q26.3 and is extending in a 750 kb genomic region, where it holds the
single-exon of SOX2 gene in its intronic region in the same strand and
orientation. (B) The splicing patterns of SOX2OT and (C) SOX2DOT isoforms
are presented, respectively.
SOX2OT gene is transcribed by RNA polymerase II enzyme, and
produces a mRNA-like lncRNA transcript (Numata et al., 2003;
Amaral et al., 2009).
Human and mouse SOX2OT have multiple TSSs, and several
alternatively spliced variants and polyadenylation sites have
already been reported for them (Amaral et al., 2009). Several
full-length clones of mouse sox2ot have been registered with a
wide range of sizes, from 638 nucleotides (GenBank accession
no. BY721402) to an approximately 3.5 kb form (accession no.
AK031919). The various sizes of the registered cDNA clones are
in accordance with the Northern blot data obtained from several
mouse tissues. While the most abundant isoform of sox2ot posses
a size of 3 kb, several other rare ones with approximate sizes of
1, 4, 6, and>10 kb have also been reported in somemouse tissues.
In zebrafish embryo, Northern blot analysis revealed an abundant
2.5 kb transcript variant and two other less abundant transcripts
of 1.5 and 6 kb (Amaral et al., 2009).
As we have previously reported, SOX2OT is spliced into
several transcript variants, including SOX2OT, SOX2OT-S1, and
SOX2OT-S2 which co-upregulated with master regulators of
pluripotency, SOX2 and OCT4, in esophageal squamous cell
carcinoma (ESCC). SOX2OT-S1 (Accession no: JN711430, GI:
379031002) lacks exon 4 of themain transcript, whereas SOX2OT-
S2 (SOX2OT-S2; Accession no: JN882275, GI: 379031003) lacks
exons 3 and 4. In addition to the experimentally approved novel
transcripts, human EST database (dbEST) also provided some
ESTs with GenBank accession numbers BX423294.2, BX442540.2,
BX459910.2, DA268964.1, and DA282731.1 which are related to
the novel sequence of exon 3-exon five junction in SOX2OT-S1,
and DA308672.1 which is related to the novel sequence of exon 2-
exon five junction in SOX2OT-S2 variant (Shahryari et al., 2014).
More than 15 differentMajor Class of introns (GT-AG), at least
13 spliced variants, and six TSSs were presented for SOX2OT
using bioinformatics analysis and AceView annotation (Amaral
et al., 2009). Our group has been also identified several novel
variants of SOX2DOT, which demonstrates a complex pattern of
TSSs and alternative splicing of SOX2OT (Figure 3A). According
to the validated NCBI Reference Sequence (RefSeqs), splicing
patterns of SOX2OT, as illustrated in Figure 3, generates at least
six transcript variants. Among those, three variants are generated
from alternative splicing of SOX2OT, while the other three ones
are originated from SOX2DOT (Figures 3B,C).
Expression Signature of SOX2OT in
Somatic, Stem, and Cancer Cells
Sox2ot isoforms are widely expressed in whole embryo and
newborn mouse, but in adult tissues their expression is
primarily restricted to brain. It is also expressed at lower
levels in tissues where Sox2 is also expressed, such as lung,
as well as in tissues were sox2 is not expressed, such as testis.
Nevertheless, sox2dot isoform is exclusively expressed in
adult mouse brain tissues. Concomitant with Sox2, Sox2ot is
mainly expressed in mouse embryonic stem cells and down-
regulated during the course of differentiation. Nevertheless,
only Sox2ot is upregulated during the late mouse embryoid
body differentiation events. Moreover, expression of Sox2 and
Sox2ot are coregulated during mouse neurosphere differentiation
in vitro. Accordingly, Sox2dot isoform is also upregulated
upon the induction of differentiation in neurospheres.
Similar to mouse, Sox2ot and sox2 are also dynamically
regulated during embryogenesis of other vertebrate, including
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FIGURE 4 | Expression signature of SOX2OT and its correlations
with other genes in human. (A,B) Approximate expression profiles of
SOX2OT and SOX2 based on ESTs (dbEST) distribution in human tissues,
and tumors libraries; the data is presented according to TPM (transcript
per million) in pool. High enrichment of SOX2OT expression in CNS libraries
and also brain-derived tumors is noticeable. (C) Two dimensional display of
gene expression summary of SOX2OT SAGE expression represents
positive and negative significant correlation with multiple key genes
involved cancer progression, stem cell pluripotency, and development. The
data was adopted from available SAGE libraries of the cancer genome
anatomy project database [Cancer Genome Anatomy Project (CGAP)]
(http://cgap.nci.nih.gov). Ten positively correlated genes (R > 0.9 top of
map) and 10 negatively correlated ones (R <  0.35, bottom of map) are
listed (P: P value, R: correlation value).
chicken and zebrafish (Mercer et al., 2008; Amaral et al.,
2009).
The lncRNA SOX2OT is co-upregulated withmaster regulators
of pluripotency, SOX2 and OCT4, in ESCC. The qRT-PCR
analysis revealed a high level of SOX2OT expression in tumor
samples of ESCC, compared to the apparently non-tumor
marginal tissues from the same patients, which suggested a
potential part for it in tumorigenesis of esophagus (Shahryari
et al., 2014).
A concomitant expression pattern of SOX2OT with that of
SOX2 and OCT4 genes is reported in a pluripotent cell line,
NT2. SOX2OT and its variants also proved to have a distinct
expression pattern during neural differentiation of NT2 cells.
The expression pattern of SOX2OT variants was similar to those
of SOX2 and OCT4, and downregulated upon the induction
of neural differentiation. However, in contrast to a complete
shut-down of SOX2 and OCT4 expression, a low expression of
SOX2OT and its variants is persisted in later time points of
differentiation (Shahryari et al., 2014).
Distinct differences in the expression patterns of SOX2OT and
SOX2 were observed in breast cancer tissue samples. Analysis
of the genome-wide RNA transcript profiles from the Cancer
Genome Atlas (breast invasive carcinoma gene expression) by
RNA Seq data set in 1106 samples of breast cancer tissues revealed
the concordant expression of SOX2OT and SOX2 in this somatic
cancer. SOX2OT and SOX2 are highly expressed in estrogen
receptor positive (ER+) breast cancer cell lines, in comparison
with the ER  ones. In ER+ breast cancer cell lines, expression
of SOX2OT is positively correlated with SOX2 expression level,
albeit at lower levels. Moreover, SOX2OT and SOX2 are co-
upregulated in suspension culture conditions of breast cancer
cell lines which advocates the growth of cellular subpopulation
with cancer stem cell-like properties (Askarian-Amiri et al.,
2014).
Overexpression of both SOX2OT and SOX2 has been reported
in human primary lung cancer tissues, in comparison with
the corresponding non-tumor samples. Furthermore, SOX2OT
demonstrated a significant high expression level in SCC of the
lung, compared with adenocarcinoma ones. There was a positive
correlation between SOX2OT and SOX2 expression levels in the
same lung cancer tissue samples (Hou et al., 2014).
In order to expand our knowledge of expression regulations, we
reviewed some resources on gene expression profile of SOX2OT
and SOX2. Exploring the expressed sequence tags (ESTs) profiles
which are available from NCBI, demonstrated the expression
patterns of SOX2 and its overlapping transcript in multiple pools
of different human tissues and tumors. The data represent the
possibility of SOX2OT and SOX2 expression in a wide list of
human tissues including brain, connective tissue, esophagus,
eye, intestine, kidney, lung, muscle, nerve, and testis. More
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interestingly, the data hint the possibility of upregulation of
SOX2OT expression in glioma and kidney tumors. In agreement
with the data reported by Amaral et al. (2009) our results also
revealed a high enrichment of SOX2OT expression in CNS
libraries (Figures 4A,B). The high expression of SOX2OT and
some other lncRNAs in CNS tissues suggests a potential role for
them in animal brain development and function (Amaral and
Mattick, 2008).
We also evaluated cancer genome anatomy project
resources [Cancer Genome Anatomy Project (CGAP)] to
find out a correlation between the expression signatures of
SOX2OT with that of other genes. Based on SAGE (Serial
Analysis of Gene Expression) data, SOX2OT represented a
significant positive and negative correlation with multiple
key genes involved in neuronal development (e.g., LRRC4B)
addressing its function in CNS development. Furthermore,
cancer associated genes (e.g., ROCK2, NFKB) are also
significantly correlated with SOX2OT in SAGE libraries;
which highlighted the potential function of SOX2OT in cancer
progression. Noticeably, a significant positive correlation of
POU3F2 transcription factor which had multiple binding
sites in genomic regulatory region of SOX2OT was observed
(Figure 4C).
The Potential Roles of SOX2OT in
Pluripotency and/or Tumorigenesis
Through Regulation of SOX2 Expression
Transcription factor SOX2 regulates the expression of more
than one thousand genes in stem cells where small changes of
its expression strikingly alter the self-renewal and pluripotency
properties; hence SOX2 acts role as a molecular rheostat in those
cells (Boyer et al., 2005; Boer et al., 2007; Kopp et al., 2008;
Amaral et al., 2009; Mandalos et al., 2014). Recent evidences
have demonstrated that gene amplification and/or aberrant
expression level of SOX2 play a role in the development and
tumorigenesis of many types of cancer including pancreatic
carcinoma, prostate, breast, lung, gastric, and esophagus cancers
(Gure et al., 2000; Sattler et al., 2000; Sanada et al., 2006;
Rodriguez-Pinilla et al., 2007; Chen et al., 2008; Jia et al., 2011;
Hütz et al., 2013). SOX2 is also involved in the proliferation and
anchorage-independent growth of esophageal and lung cell lines.
SOX2-driven tumors expressed both squamous differentiation
and pluripotency markers which introduced SOX2 as a lineage-
survival oncogene in SCC of both lung and esophagus (Bass et al.,
2009). Nevertheless, the exact regulation of SOX2 in pathway-
dependent pluripotency and tumorigenesis has not been fully
addressed yet.
LncRNAs have been suggested to regulate the expression
of neighboring overlapped or antisense genes via different
mechanisms (Mercer et al., 2009; Hung and Chang, 2010).
The location of SOX2 gene within the intronic region of
SOX2OT gene proposed a possibility for SOX2 expression
regulation by SOX2OT. This hypothesis is more approved by
several experimental approaches obtained from gene expression
alteration during stem cell differentiation or carcinogenesis, and
also by manipulation of SOX2OT expression in vitro (Amaral
et al., 2009; Askarian-Amiri et al., 2014; Hou et al., 2014; Shahryari
et al., 2014). Similar dynamic regulation of sox2ot transcripts
and sox2 proposed a conserved role for sox2ot in vertebrate
embryogenesis and neuronal system development (Amaral et al.,
2009).
Using the RNA interference strategy, our group performed
a functional assay on SOX2OT, where the data supported our
hypothesis on the existence of a positive regulation of SOX2 and
OCT4 by SOX2OT (Shahryari et al., 2014). In line with the data,
Askarian-Amiri et al. (2014) demonstrated that ectopic expression
of SOX2OT caused increased SOX2 expression level. They also
demonstrated that the enriched suspension culture of breast
cancer cells, which favors stem cell growth, exhibited upregulation
of both SOX2 and SOX2OT expression, in comparison to the
original adherent cells (Askarian-Amiri et al., 2014).
Furthermore, SOX2OT exerts regulatory function in cell
cycle progression; hence its association with carcinogenesis of
human tumors of breast (Askarian-Amiri et al., 2014), esophagus
(Shahryari et al., 2014), and lung (Hussenet et al., 2010; Hou et al.,
2014) cancers is not surprising. SOX2OT controls lung cancer
cell proliferation, and represents a novel prognostic indicator for
this cancer (Hou et al., 2014). The knocking down of SOX2OT
caused induction of G2/M arrest, prohibition of S phase entry
and inhibited cell proliferation which correlated with reduced
protein levels of Cyclin B1 and Cdc2 in human lung cancer
cell lines. SOX2OT moderated lung cancer cell cycle progression
through regulating EZH2 expression level; albeit any evidence of
physical interaction between them has not been observed (Hou
et al., 2014). EZH2 (a histone-lysineN-methyltransferase enzyme)
is a major component of the polycomb repressive complex 2
(PRC2) which is involved in maintaining the transcriptional
repressive state of its target genes (Cardoso et al., 2000; Cao et al.,
2002).
High expression levels of SOX2OT and SOX2 are associated
with estrogen receptor status and tamoxifen sensitivity of breast
cancer cells (Askarian-Amiri et al., 2014). SOX2OT and SOX2 co-
upregulation has been reported in lung tumor tissues, particularly
in squamous cell lung carcinoma (Hussenet et al., 2010; Hou
et al., 2014), which is related to 3q26.33 genomic amplification
(Hou et al., 2014). A statistically significant correlation coefficient
between SOX2 and SOX2OT in cancer tissues (Askarian-Amiri
et al., 2014; Hou et al., 2014; Shahryari et al., 2014), suggested
the possibility of SOX2OT role in the regulation of SOX2
expression.
Altogether, current evidences indicate a functional association
between SOX2OT and SOX2 in tumorigenesis, cellular
differentiation, and pluripotency (Table 1). Yet, more remains to
be investigated on the mechanisms underlying this regulation.
Concluding Remarks
According to recent achievements, a large number of lncRNAs
primarily exert their biological functions through induction
of epigenetic events including DNA methylation or histon
modifications in their target genes. This is mediated by the
well-known chromatin modifying complexes of PRC1 and
PRC2, as well as other related complexes in a cis- or trans-
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TABLE 1 | Recent studies which highlighted emerging roles of SOX2OT in pluripotency and carcinogenesis.
Reference SOX2OT association with pluripotency or carcinogenesis SOX2OT status
Amaral et al. (2009) Vertebrate embryos Upregulated
Embryonic body differentiation Downregulated
Hussenet et al. (2010) Squamous cell carcinoma of lung with Upregulated
3q.26 amplification
Askarian-Amiri et al. (2014) Estrogen positive to estrogen negative Upregulated
breast cancer tissue
Tamoxifen resistant breast cancer cell Downregulated
lines
Suspension culture enriched Upregulated
breast cancer cell
Shahryari et al. (2014) Esophagus squamous cell tumor to normal Upregulated
tissue
NT2 neuronal like differentiation Downregulated
Hou et al. (2014) Lung cancer of squamous and Upregulated
adenocarcinoma to normal tissue
acting manner (Prensner and Chinnaiyan, 2011; Wang and
Chang, 2011; Brockdorff, 2013). Multiple lncRNAs including
HOTAIR, ANCR, and ANRIL are able to recruit PRC1 or PRC2
complexes to genomic regulatory regions of their target genes
to reshape/regulate the chromatin state/their expression (Gupta
et al., 2010; Aguilo et al., 2011; Kretz et al., 2012).
LncRNA ANRIL is involved in various mechanisms of
epigenetic regulation including triggering a repression of INK4
locus by SUZ12 in PRC2 (Kotake et al., 2011), an induction of
chromatin silencing of the CDKN2A/B genes through interaction
with CBX7 in PRC1 (Yap et al., 2010), and an alteration of DNA
methylation of the locus in differentiated cells (Yu et al., 2008).
Genomic association of SOX2 and SOX2OT remarkably resembles
that of ANRIL and CDKN2B. Similarly, the lncRNA ANRIL holds
the protein-coding gene CDKN2B in its intronic region, albeit in
the antisense/opposite strand.
A brain specific lncRNA known as RMST which is involved
in modulating neurogenesis physically interacts with SOX2. By
acting as a transcriptional coregulator, RMST helps SOX2 to bind
to regulatory regions of that of target genes which have a role in
the regulation of neural stem cell fate (Ng et al., 2013). Although
recent studies on SOX2OT and SOX2 have not claimed the
existence of any physical interaction between them, the functional
assays obtained from both knockdown and overexpression events
have demonstrated that SOX2OT has a positive effect on SOX2
expression (Askarian-Amiri et al., 2014; Shahryari et al., 2014).
As it was mentioned above, SOX2OT regulated the expression of
EZH2 (in PRC2); however, the exact mechanism of regulation of
SOX2 expression by SOX2OTmediated either by regulating PRC2
or other molecular mechanism remained largely questionable.
Several isoforms of Sox2ot which originated from alternative
TSSs are associated with chromatin modifications characteristic
of well-known promoters in HCEs. These isoforms have tissue
or cell type specific signature, and are differentially regulated
(Kimura et al., 2006; Denoeud et al., 2007; Amaral et al., 2009).
This event is more prominent in SOX2DOT isoform which has
a specific tissue expression pattern restricted to the adult mouse
brain. SOX2DOT also demonstrates different expression patterns
during differentiation of ESCs and neurospheres. The existence
of alternative splicing and alternative TSSs suggests that the
different transcripts of Sox2ot might have differential regulation
and function (Amaral et al., 2009).
Moreover, according to the sequences registered for SOX2OT
in EST database of NCBI, it is deduced that SOX2OT could
have more than three splicing variants with a unique tissue or
cell type specific expression signature. Moreover, the isoform
of SOX2DOT indicates a more complex splicing pattern for
SOX2OT. Altogether, the overlapped expression of SOX2OT with
SOX2, and the conserved association between them in different
developmental systems of vertebrates, and also in human cancer
and stem cells all support the existence of a complex functional
regulatory relationship. The latter could be a consequence of
having similar regulatory elements that regulate the expression of
both Sox2ot and Sox2 (Amaral et al., 2009; Askarian-Amiri et al.,
2014; Shahryari et al., 2014).
Several conserved genomic regions upstream of SOX2OT
and SOX2DOT serve as the binding sites for key transcription
factors responsible for controlling the pluripotency as well
as tumorigenesis processes. This observation along with the
observed correlations between the expression of SOX2OT
variants with that of key genes promoting those events,
all suggested a key role for SOX2OT in pluripotency and
tumorigenesis.
In this review we have provided insights into structural
characteristics, epigenetic modifications, and splicing patterns
of SOX2OT gene. Furthermore, the expression patterns of
its variants and their emerging roles in stem cell biology
and tumorigenesis is discussed. It is clear that SOX2OT has
a positive regulatory effect on SOX2 expression; however,
the exact molecular mechanism remains to be elucidated.
Specifying SOX2OT-dependent molecular pathways in organ
tissue culture or engineered animal models may identify more
common pathways between development, pluripotency and
tumorigenesis.
In conclusion, current evidences support the idea that
the lncRNA SOX2OT is a key regulatory molecule in
mediating pluripotency and tumorigenesis events, probably
through regulation of SOX2 expression. The positive effect of
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SOX2OT upon SOX2 expression also supports a role for it in
promoting generation of iPSCs. SOX2OT has a potential to be
employed as a novel prognostic indicator/therapeutic target of
several human cancers including breast, lung and esophagus
cancers.
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